ConductScience.org, home

Paper40445936

Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19.

Yan H and 8 others. PLoS One, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19. Papers, record 40445936. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40445936

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19.
PubMed
Journal
PLoS One
PubMed
Year
2025
PubMed
Publication types
Journal Article, Observational Study, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-10-08
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yan HHan
2Hu SShanbiao
3Zhang HHedong
4Zhou YYangang
5Fu RRao
6Xu PPing
7Cai HHualin
8Li XXi
9Lan GGongbinhttps://orcid.org/0000-0001-6500-5820

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
COVID-19 Drug TreatmentMajor topic
Immunosuppressive AgentsMajor topic
Kidney TransplantationMajor topic
RitonavirMajor topic
TacrolimusMajor topic
Adult
Aged
Female
Humans
Male
Middle Aged
COVID-19
Drug Therapy, Combination
Retrospective Studies
SARS-CoV-2
Transplant Recipients

Source PubMed

Download CSV of topics

References36

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132382127NKG2A and COVID-19: another brick in the wall.Cell Mol Immunol2020https://conductscience.org/library/papers/32382127PubMed
233278850Incidence and outcome of SARS-CoV-2 infection on solid organ transplantation recipients: A nationwide population-based study.Am J Transplant2021https://conductscience.org/library/papers/33278850PubMed
335713302Single-center experience with nirmatrelvir/ritonavir in kidney transplant recipients on tacrolimus maintenance immunosuppression.Clin Transplant2022https://conductscience.org/library/papers/35713302PubMed
435618549Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT).Therapie2022https://conductscience.org/library/papers/35618549PubMed
535816278Paxlovid-Tacrolimus Drug-Drug Interaction in a 23-Year-Old Female Kidney Transplant Patient with COVID-19.Clin Drug Investig2022https://conductscience.org/library/papers/35816278PubMed
625386767An interferon-free antiviral regimen for HCV after liver transplantation.N Engl J Med2014https://conductscience.org/library/papers/25386767PubMed
733246166COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature.Transplant Rev (Orlando)2021https://conductscience.org/library/papers/33246166PubMed
837477905Drug-drug interaction of Nirmatrelvir/ritonavir and tacrolimus: A potential risk disproportionality analysis of nephrotoxicity from COVID-19 reports in FAERS.Expert Opin Drug Saf2023https://conductscience.org/library/papers/37477905PubMed
935653428Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.Clin Infect Dis2023https://conductscience.org/library/papers/35653428PubMed
1033101306Covid-19: Perspectives on Innate Immune Evasion.Front Immunol2020https://conductscience.org/library/papers/33101306PubMed
1135944126Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19.Ther Drug Monit2023https://conductscience.org/library/papers/35944126PubMed
1221937987Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy.Clin Pharmacol Ther2011https://conductscience.org/library/papers/21937987PubMed
1335172054Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.N Engl J Med2022https://conductscience.org/library/papers/35172054PubMed
1433988341Outcomes of COVID-19 in Solid Organ Transplant Recipients: A Propensity-matched Analysis of a Large Research Network.Transplantation2021https://conductscience.org/library/papers/33988341PubMed
1536847419"Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".Transpl Infect Dis2023https://conductscience.org/library/papers/36847419PubMed
1634695836Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells.Nature2021https://conductscience.org/library/papers/34695836PubMed
1735599203Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report.Transplant Proc2022https://conductscience.org/library/papers/35599203PubMed
1834017137CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer.Nat Med2021https://conductscience.org/library/papers/34017137PubMed
1925708713Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir.Am J Transplant2015https://conductscience.org/library/papers/25708713PubMed
2034087553The association between severe or death COVID-19 and solid organ transplantation: A systematic review and meta-analysis.Transplant Rev (Orlando)2021https://conductscience.org/library/papers/34087553PubMed

See all 36 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
42965158Drug Rescue for Paxlovid-Induced Tacrolimus Toxicity: A Pooled Analysis of Case Reports.Kidney Med2026https://conductscience.org/library/papers/42965158

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40445936

GET https://conductscience.org/api/papers/v1/40445936/references?page=2